More invasive tissue sampling in other studies has shown that dupilumab can suppress type 2 biomarker levels in target organs, such as suppression of ECP, eotaxin‐1, eotaxin‐2, eotaxin‐3, pulmonary and activation‐regulated chemokine (PARC), IgE and IL‐13 in nasal polyp tissue of CRSwNP patients in a phase 2 study;7 and suppression of ECP, total IgE, eotaxin‐3 and IL‐5 in nasal secretions in SINUS‐52.23 Here, CCL26 is linked to chronic rhinosinusitis with nasal polyps.